Drug intelligence / Profile preview

IVW-1902

Development stage: Preclinical
Lead developer: IVIEW Therapeutics
Modality: Small Molecules
Administration: Ophthalmic

Overview

IVW-1902 (also known as IVIEW-1902) is a preclinical-stage small molecule ophthalmic eye drop being developed by IVIEW Therapeutics (IVIEW Pharmaceutical) for the treatment of presbyopia. Presbyopia is a progressive, age-related loss of near vision accommodation. IVW-1902 is designed to improve near vision through topical administration to the eye. As of 2026, the candidate remains in preclinical development.

Other names: IVIEW 1902IVIEW1902IVIEW-1902IVW 1902IVW1902IVW-1902

Beyond the preview

Go deeper on IVW-1902.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVW-1902.

Explore the full profile